I begge undersøgelser viste patienter med sekundær progressiv dissemineret sklerose en reduktion i hyppighed (30%) af kliniske relapser.
In both trials secondary progressive multiple sclerosis patients receiving Betaferon showed a reduction in frequency (30%) of clinical relapses.